Technologies of diagnosis and treatment


The treatment of refractory angina. The place of ranolazine

O.A. Yepanchintseva 1, 2, O.J. Zharinov 2 , I.V. Shklianka 1, A.V. Khokhlov 1

1 Heart Institute, Healthcare Ministry of Ukraine, Kyiv, Ukraine
2 Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine

The article discusses the mechanisms of refractoriness to antianginal therapy in patients with stable ischemic heart disease. The clinical case demonstrates the possibility of using ranolazine in addition to first-line treatment of refractory angina in case of impossibility of myocardial revascularization. According to the current international guidelines, the use of ranolazine should be considered as an adjunct to basic therapy of the ischemic heart disease in case of impossibility of myocardial revascularization, refractory angina and multivessel coronary atherosclerosis. The results of many clinical studies have proven the anti-ischemic effect and safety of ranolazine after coronary artery stenting. A special emphasis is made on the importance of multicomponent correction of risk factors.

Key words: stable coronary heart disease, refractory angina, drug treatment, ranolazine.

[PDF] [References]